-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Isracann Biosciences Signs Definitive Agreement To Acquire Praesidio Health For $3.18M
Isracann Biosciences Signs Definitive Agreement To Acquire Praesidio Health For $3.18M
Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE:IPOT) (XFRA:A2PT0E) signed a definitive agreement dated March 24, 2022 with Praesidio Health Inc to acquire all of the issued and outstanding shares in the capital of Praesidio for CA$4 million ($3.18 million) in common shares of the company. Upon closing of the transaction, Praesidio will operate as a wholly-owned subsidiary of the company.
Praesidio Health is a Canadian medical research company that develops and validates natural health medicine using an evidence-based process. Pioneering NHMs and therapeutics, Praesidio Health is actively developing several product candidates for utility in a range of conditions, including post-viral exposure prophylaxis, urological, anxiety/stress, immune booster, and sleep aids. The company employs formulation combinations with and without cannabinoids and/or psilocybin, which opens the opportunity for product development in conjunction with future operations in Israel including direct access to European markets.
The consideration shares will be issued in seven tranches, with CA$1 million of the consideration shares being issued at closing and CA$500,000 of the consideration shares being issued every six months thereafter until the third anniversary of the date of closing. The price of the consideration shares will be equal to the volume weighted average of actual trading prices (measured in hundredths of cents) of the common shares in the capital of the company on the Canadian Securities Exchange for the ten consecutive business days prior to the applicable date of issuance. The consideration shares will be subject to a 48-month contractual escrow period, which will begin on date of closing.
The transaction remains subject to certain closing conditions, including, without limitation, the receipt of all necessary corporate and regulatory approvals and other customary closing conditions. There can be no assurance that the transaction will be completed as proposed or at all. Closing of the transaction is expected to occur on or about April 4th, 2022.
Related News
Isracann Signs Preliminary Deal For European Cannabis Distribution
Â
Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE:IPOT) (XFRA:A2PT0E) signed a definitive agreement dated March 24, 2022 with Praesidio Health Inc to acquire all of the issued and outstanding shares in the capital of Praesidio for CA$4 million ($3.18 million) in common shares of the company. Upon closing of the transaction, Praesidio will operate as a wholly-owned subsidiary of the company.
Isracann Biosciences Inc.(OTCPK:ISCNF)(CSE:IPOT)(XFRA:A2PT0E)与Praesidio Health Inc.于2022年3月24日签署了最终协议收购所有已发行及流通股在普拉西迪奥的首府CA$4 318万美元(318万美元)在公司的普通股中c公司。交易完成后,Praesidio将作为该公司的全资子公司运营。
Praesidio Health is a Canadian medical research company that develops and validates natural health medicine using an evidence-based process. Pioneering NHMs and therapeutics, Praesidio Health is actively developing several product candidates for utility in a range of conditions, including post-viral exposure prophylaxis, urological, anxiety/stress, immune booster, and sleep aids. The company employs formulation combinations with and without cannabinoids and/or psilocybin, which opens the opportunity for product development in conjunction with future operations in Israel including direct access to European markets.
Praesidio Health是一家加拿大医学研究公司它使用循证过程开发和验证自然健康药物。作为NHM和治疗学的先驱,Praesidio Health正在积极开发几种适用于一系列条件的候选产品,包括病毒暴露后预防、泌尿外科、焦虑/压力、免疫增强剂和睡眠辅助设备。该公司使用含和不含的配方组合大麻素和/或裸盖菇素,这为产品开发和未来在以色列的业务提供了机会,包括直接进入欧洲市场。
The consideration shares will be issued in seven tranches, with CA$1 million of the consideration shares being issued at closing and CA$500,000 of the consideration shares being issued every six months thereafter until the third anniversary of the date of closing. The price of the consideration shares will be equal to the volume weighted average of actual trading prices (measured in hundredths of cents) of the common shares in the capital of the company on the Canadian Securities Exchange for the ten consecutive business days prior to the applicable date of issuance. The consideration shares will be subject to a 48-month contractual escrow period, which will begin on date of closing.
对价股份将分七批发行,其中1,000加元的对价股份于交易结束时发行,500,000加元的对价股份此后每六个月发行一次,直至交易结束日期的三周年为止。对价股份的价格将等于适用发行日期前连续十个工作日公司资本中普通股在加拿大证券交易所的实际交易价(以百分之一美分计算)的成交量加权平均值。对价股份将有48个月的合同托管期,从成交之日开始。
The transaction remains subject to certain closing conditions, including, without limitation, the receipt of all necessary corporate and regulatory approvals and other customary closing conditions. There can be no assurance that the transaction will be completed as proposed or at all. Closing of the transaction is expected to occur on or about April 4th, 2022.
交易仍受某些成交条件的制约,包括但不限于获得所有必要的公司和监管部门的批准以及其他惯常的成交条件。不能保证这笔交易将按计划完成,或者根本不能保证。电子邮件交易预计将于4月4日左右完成。这是, 2022.
Related News
相关新闻
Isracann Signs Preliminary Deal For European Cannabis Distribution
Isracann签署欧洲大麻分销初步协议
Â
Â
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧